Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex

Brain Research

Volumn 989, Issue 1, 2003, Pages 42-51

  Czyrak, Anna ^a   Czepiel, Klaudia ^a   Maćkowiak, Marzena ^a   Chocyk, Agnieszka ^a   Wȩdzony, Krzysztof ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT1A Receptor; Double labeling; Glutamate; Immunohistochemistry; Neurofilament H; Parvalbumin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; GLUTAMIC ACID; NEUROFILAMENT PROTEIN; PROTEIN SUBUNIT; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN FUNCTION; CELL SHAPE; CELL SIZE; CELLULAR DISTRIBUTION; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; GABAERGIC TRANSMISSION; GLUTAMATERGIC NERVE CELL; IMMUNOREACTIVITY; MALE; NERVE ENDING; NERVE FIBER; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RAT; RECEPTOR SENSITIVITY; SCHIZOPHRENIA; SPATIAL ORIENTATION;

EID: 0142102450     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03352-3     Document Type: Article

References (73)

1. Andersen H.L., Kilpatrick I.C. Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. Br. J. Pharmacol. 118:1996;421-427.
2. Anthony T.E., Azmitia E.C. Molecular characterization of antipeptide antibodies against the 5-HT1A receptor: evidence for state-dependent antibody binding. Brain Res. Mol. Brain Res. 50:1997;277-284.
3. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 148:1993;465-466.
4. Azmitia E.C., Yu I., Akbari H.M., Kheck N., Whitaker-Azmitia P.M., Marshak D.R. Antipeptide antibodies against the 5-HT1A receptor. J. Chem. Neuroanat. 5:1992;289-298.
5. Azmitia E.C., Gannon P.J., Kheck N.M., Whitaker-Azmitia P.M. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology. 14:1996;35-46.
6. Bantick R.A., Deakin J.F., Grasby P.M. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J. Psychopharmacol. 15:2001;37-46.
7. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
8. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 25:2001;1-27.
9. Brambilla P., Nicoletti M.A., Harenski K., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology. 27:2002;792-799.
10. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
11. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30:1997;565-574.
12. Campbell M.J., Morrison J.H. Monoclonal antibody to neurofilament protein (SMI-32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex. J. Comp. Neurol. 282:1989;191-205.
13. Celio M.R. Parvalbumin in most gamma-aminobutyric acid-containing neurons of the rat cerebral cortex. Science. 231:1986;995-997.
14. Chalmers D.T., Watson S.J. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain - a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res. 561:1991;51-60.
15. Christoffersen C.L., Meltzer L.T. Reversal of haloperidol-induced extrapyramidal side-effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology. 18:1998;399-402.
16. + channel densities in the soma and axon initial segment of subicular pyramidal neurons. J. Neurosci. 16:1996;6676-6686.
17. Czyrak A., Maćkowiak M., Chocyk A., Fijalł K., Michalska-Ga̧dek A., Wȩdzony K. OHDPAT-induced disruption of prepulse inhibition in rats is attenuated by prolonged corticosterone treatment. Neuropsychopharmacology. 28:2003;1300-1310.
18. Czyrak A., Mackowiak M., Chocyk A., Fijal K., Tokarski K., Bijak M., Wedzony K. Prolonged corticosterone treatment alters the responsiveness of 5-HT(1A) receptors to 8-OH-DPAT in rat CA1 hippocampal neurons. Naunyn Schmiedebergs Arch. Pharmacol. 366:2002;357-367.
19. De Vry J. 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berlin). 121:1995;1-26.
20. DeFelipe J., Arellano J.I., Gomez A., Azmitia E.C., Munoz A. Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. J. Comp. Neurol. 433:2001;148-155.
21. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav. Pharmacol. 11:2000;223-233.
22. Ellenbroek B.A., Budde S., Cools A.R. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience. 75:1996;535-542.
23. el Mestikawy S., Riad M., Laporte A.M., Verge D., Daval G., Gozlan H., Hamon M. Production of specific anti-rat 5-HT1A receptor antibodies in rabbits injected with a synthetic peptide. Neurosci. Lett. 118:1990;189-192.
24. Goff D.C., Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. 27:1997;157-168.
25. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry. 42:1997;529-545.
26. Harder J.A., Ridley R.M. The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology. 39:2000;547-552.
27. Hashimoto T., Nishino N., Nakai H., Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
28. Hendry S.H., Houser C.R., Jones E.G., Vaughn J.E. Synaptic organization of immunocytochemically identified GABA neurons in the monkey sensory-motor cortex. J. Neurocytol. 12:1983;639-660.
29. Hendry S.H., Jones E.G., Emson P.C., Lawson D.E., Heizmann C.W., Streit P. Two classes of cortical GABA neurons defined by differential calcium binding protein immunoreactivities. Exp. Brain Res. 76:1989;467-472.
30. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
31. Hurley K.M., Herbert H., Moga M.M., Saper C.B. Efferent projections of the infralimbic cortex of the rat. J. Comp. Neurol. 308:1991;249-276.
32. Ichikawa J., Kuroki T., Kitchen M.T., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur. J. Pharmacol. 287:1995;179-184.
33. Jakab R.L., Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA. 95:1998;735-740.
34. Jakab R.L., Goldman-Rakic P.S. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J. Comp. Neurol. 417:2000;337-348.
35. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
36. Kia H.K., Miquel M.C., Brisorgueil M.J., Daval G., Riad M., el Mestikawy S., Hamon M., Verge D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 365:1996;289-305.
37. Killcross A.S., Stanhope K.J., Dourish C.T., Piras G. WAY100635 and latent inhibition in the rat: selective effects at preexposure. Behav. Brain Res. 88:1997;51-57.
38. Kuroki T., Ichikawa J., Dai J., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743:1996;357-361.
39. Lacroix L., Broersen L.M., Weiner I., Feldon J. The effects of excitotoxic lesion of the medial prefrontal cortex on latent inhibition, prepulse inhibition, food hoarding, elevated plus maze, active avoidance and locomotor activity in the rat. Neuroscience. 84:1998;431-442.
40. Lacroix L., Spinelli S., White W., Feldon J. The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion. Neuroscience. 97:2000;459-468.
41. Lewis D.A., Pierri J.N., Volk D.W., Melchitzky D.S., Woo T.U. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol. Psychiatry. 46:1999;616-626.
42. Lipska B.K., Jaskiw G.E., Braun A.R., Weinberger D.R. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol. Psychiatry. 38:1995;255-262.
43. Loscher W., Honack D. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242:1993;99-104.
44. Lucas G., Bonhomme N., De Deurwaerdere P., Le Moal M., Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berlin). 131:1997;57-63.
45. Mackowiak M., Chocyk A., Fijal K., Czyrak A., Wedzony K. c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Brain Res. Mol. Brain Res. 71:1999;358-363.
46. Mason S.L., Reynolds G.P. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur. J. Pharmacol. 221:1992;397-398.
47. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
48. Newman-Tancredi A., Chaput C., Verriele L., Millan M.J. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology. 35:1996;119-121.
49. 35S]GTPgammaS binding study. Eur. J. Pharmacol. 355:1998;245-256.
50. Ottersen O.P., Storm-Mathisen J. Localization of amino acid neurotransmitters by immunocytochemistry. Trends Neurosci. 10:1987;250-255.
51. Ottersen O.P., Storm-Mathisen J. Glutamate- and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunocytochemical technique. J. Comp. Neurol. 229:1984;374-392.
52. Ottersen O.P., Storm-Mathisen J. Excitatory amino acid pathways in the brain. Adv. Exp. Med. Biol. 203:1986;263-284.
53. Paxinos G. The Rat Nervous System. 1995;Academic Press.
54. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th Edition: 1998;Academic Press, San Diego.
55. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
56. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12:1992;440-453.
57. Raymond J.R., Mukhin Y.V., Gettys T.W., Garnovskaya M.N. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br. J. Pharmacol. 127:1999;1751-1764.
58. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631:1993;191-202.
59. Sesack S.R., Pickel V.M. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J. Comp. Neurol. 320:1992;145-160.
60. Somogyi P. A specific 'axo-axonal' interneuron in the visual cortex of the rat. Brain Res. 136:1977;345-350.
61. Sternberger L.A., Sternberger N.H. Monoclonal antibodies distinguish phosphorylated and non-phosphorylated forms of neurofilaments in situ. Proc. Natl. Acad. Sci. USA. 80:1983;6126-6130.
62. Stuart G.J., Sakmann B. Active propagation of somatic action potentials into neocortical pyramidal cell dendrites. Nature. 367:1994;69-72.
63. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Dilley G.E., Meltzer H.Y. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1996;209-214.
64. Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophysiol. 69:1993;1749-1757.
65. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20:1996;325-339.
66. Waeber C., Dietl M.M., Hoyer D., Palacios J.M. 5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography. Naunyn Schmiedebergs Arch. Pharmacol. 340:1989;486-494.
67. Wedzony K., Mackowiak M., Fijal K., Golembiowska K. Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur. J. Pharmacol. 305:1996;73-78.
68. Wedzony K., Mackowiak M., Zajaczkowski W., Fijal K., Chocyk A., Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology. 23:2000;547-559.
69. Wedzony K., Mackowiak M., Czyrak A., Fijal K., Michalska B. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res. 756:1997;84-91.
70. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., Berman K.F., Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry. 50:2001;825-844.
71. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br. J. Psychiatry. 172:1998;243-249.
72. Woo T.U., Whitehead R.E., Melchitzky D.S., Lewis D.A. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. USA. 95:1998;5341-5346.
73. Zahrt J., Taylor J.R., Mathew R.G., Arnsten A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 17:1997;8528-8535.